



ASX Release

19 December 2024

Cleansing notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) Share Placement

Acrux Ltd (ASX:ACR) (**Company**) refers to its announcements on 5 December 2024 regarding completion of a share placement raising \$2.65 million (before costs) and on 12 December 2024 advising that the Company had partially completed the share placement issuing 65,714,262 fully paid ordinary shares (**Shares**) to institutional and professional investors at an issue price of 3.5 cents per Share.

Further to these announcements the Company advises \$0.20 million of the committed funds has been received and thereby issues 5,714,385 fully paid ordinary shares. The remaining \$0.150 million has been committed by the Company's Directors and is due to be received after approval at an Extraordinary General Meeting to be held in February 2025.

The Company gives notice under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Act**) that:

- (1) the Company issued the Shares without disclosure to investors under Part 6D.2 of the Act;
- (2) this notice is being given under section 708A(5)(e) of the Act;
- (3) as at the date of this notice, it has complied with:
 - (a) the provisions of Chapter 2M of the Act as they apply to the Company; and
 - (b) sections 674 and 674A of the Act; and
- (4) as at the date of this notice, there is no information that is "excluded information" (as defined in sections 708A(7) and (8) of the Act) which is required to be set out in this notice under section 708A(6)(e) of the Act.

This announcement has been authorised for release to the ASX by the Managing Director.

For more information, please contact:

Michael Kotsanis

CEO & Managing Director

E: michael.kotsanis@acrux.com.au

Joanna Johnson

CFO & Company Secretary

E: joanna.johnson@acrux.com.au

P: + 61 3 8379 0100

About Acrux

Acrux is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States. Acrux is formulating and developing a range of topical generic products by leveraging its highly skilled workforce, on-site laboratories, GMP manufacturing suite, technical, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss commercial partnering and product development opportunities. For further information on Acrux, visit: www.acrux.com.au